D. Boral Capital Cuts Estrella Immunopharma (NASDAQ:ESLA) Price Target to $8.00

Estrella Immunopharma (NASDAQ:ESLA) had its price objective decreased by D. Boral Capital from $16.00 to $8.00 in a research note published on Wednesday morning,Benzinga reports. D. Boral Capital currently has a buy rating on the stock.

Several other analysts also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Estrella Immunopharma in a research note on Friday, October 31st. Wall Street Zen cut Estrella Immunopharma from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Price Performance

NASDAQ:ESLA opened at $1.12 on Wednesday. The firm’s 50-day moving average price is $1.47 and its 200-day moving average price is $1.42. The company has a market capitalization of $42.30 million, a PE ratio of -3.29 and a beta of 0.55. Estrella Immunopharma has a 1-year low of $0.73 and a 1-year high of $3.15.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.